论文部分内容阅读
比较了头孢克罗缓释片和普通胶囊的药物动力学和生物利用度，８名健康志愿者随机交叉单剂量ｐｏ７５０ｍｇ缓释片和普通胶囊，采用ＨＰＬＣ法测定血浆和尿中头孢克罗浓度，缓释片和普通胶囊的药动学参数为Ｃｍａｘ７．２６±１．０８和１５．４４±３．７３μｇ／ｍｌ；Ｔｍａｘ１．１３±０．２３和０．７２±０．１６ｈ；ｔ１／２０．９４±０．１９和０．６３±０．０８ｈ；ＭＲＴ２．５１±０．４５和１．３５±０．２５ｈ，ＡＵＣ２１．６５±３．３１和２２．２４±３．６８ｈμｇ／ｍｌ。ＡＵＣ及其对数形式经三因素方差分析和双单侧检验，两种制剂均无显著性差异，缓释片的相对生物利用度为（９８．２３±１３．７３）％。
The pharmacokinetics and bioavailability of cefaclor sustained-release tablets and ordinary capsules were compared. Eight healthy volunteers were randomized to cross a single dose of po750mg sustained-release tablets and ordinary capsules. Plasma and urinary cefaclor concentrations were determined by HPLC. The pharmacokinetic parameters of sustained-release tablets and ordinary capsules were Cmax7.26 ± 1.08 and 15.44 ± 3.73μg / ml; Tmax1.13 ± 0.23 and 0.72 ± 0.16h; t1 / 20. 94 ± 0.19 and 0.63 ± 0.08 h; MRT 2.51 ± 0.45 and 1.35 ± 0.25 h, AUC 21.65 ± 3.31 and 22.24 ± 3.68 hμg / ml. AUC and its logarithmic form by three-factor analysis of variance and double unilateral test, no significant difference between the two preparations, the relative bioavailability of sustained-release tablets was (98.23 ± 13.73)%.